Neratinib Maleate Patent Expiration
Neratinib Maleate is used for treating early-stage and advanced HER2-positive breast cancer. It was first introduced by Puma Biotechnology Inc
Neratinib Maleate Patents
Given below is the list of patents protecting Neratinib Maleate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Nerlynx | US8669273 | Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine | Jul 18, 2031 | Puma Biotech |
| Nerlynx | US7399865 | Protein tyrosine kinase enzyme inhibitors | Dec 29, 2030 | Puma Biotech |
| Nerlynx | US8518446 | Coated tablet formulations and uses thereof | Nov 20, 2030 | Puma Biotech |
| Nerlynx | US8790708 | Coated tablet formulations and uses thereof | Nov 05, 2030 | Puma Biotech |
| Nerlynx | US9211291 | Treatment regimen utilizing neratinib for breast cancer | Mar 24, 2030 | Puma Biotech |
| Nerlynx | US9265784 | Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine | Aug 04, 2029 | Puma Biotech |
| Nerlynx | US10035788 | Maleate salts of (E)-N-{4[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof | Oct 15, 2028 | Puma Biotech |
| Nerlynx | US9139558 | Maleate salts of (E)-N-{4-[3-Chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof | Oct 15, 2028 | Puma Biotech |
| Nerlynx | US9630946 | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof | Oct 15, 2028 | Puma Biotech |
| Nerlynx | US7982043 | Protein tyrosine kinase enzyme inhibitors | Oct 08, 2025 | Puma Biotech |
| Nerlynx | US6288082 | Substituted 3-cyanoquinolines |
Sep 24, 2019
(Expired) | Puma Biotech |
Neratinib Maleate's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List